Mississippi mud no more: Cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity

被引:52
作者
Darko, W
Medicis, JJ
Smith, A
Guharoy, R
Lehmann, DE
机构
[1] Upstate Med Univ Hosp, Clin Pharmacol Sect, Dept Pharm, Sect Clin Pharmacol, Syracuse, NY 13210 USA
[2] Upstate Med Univ Hosp, Clin Pharmacol Sect, Dept Med, Sect Clin Pharmacol, Syracuse, NY 13210 USA
来源
PHARMACOTHERAPY | 2003年 / 23卷 / 05期
关键词
D O I
10.1592/phco.23.5.643.32199
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective. To determine the cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. An analysis was performed for subpopulations of patients receiving nephrotoxic agents (aminoglycosides, amphotericin, and acyclovir), those in the intensive care unit, and those on the oncology service. Methods. Decision analysis was used to model the cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin. The reference case was determined, in part, by a retrospective review of 200 patients randomly selected from our clinical pharmacology consultation service. Patients were aged 18 years or older and had received intravenous vancomycin for at least 48 hours, with at least two-one peak and one trough-vancomycin serum concentrations obtained during therapy. Results of published clinical trials were used to determine the probability of vancomycin-induced nephrotoxicity. Results. The mean cost of treating nephrotoxicity was $11,233 at our institution. The mean cost for all patients was $25,166 (sensitivity analysis $15,000-27,500)/nephrotoxic episode prevented. The subgroup analysis revealed a cost of $8363 (sensitivity analysis $4368-10,500)/nephrotoxic episode prevented in intensive care patients, $5000 (sensitivity analysis $1687-13,250) in oncology patients, and a dominant strategy showing a cost savings of $5564 (sensitivity analysis $2724-12,428) in those receiving concomitant nephrotoxins. Conclusion. Although pharmacokinetic monitoring and dosage adjustment are effective methods for reducing the toxicity of many drugs, controversy exists regarding the necessity of such monitoring with vancomycin. Evaluation by decision analysis over a range of assumptions, varying probabilities, and costs reveals that pharmacokinetic monitoring and vancomycin dosage adjustment to prevent nephrotoxicity are not cost-effective for all patients. However, such dosage adjustment demonstrates cost-effectiveness for patients receiving concomitant nephrotoxins, intensive care patients, and probably oncology patients.
引用
收藏
页码:643 / 650
页数:8
相关论文
共 27 条
[1]   USING CLINICAL-DATA TO DETERMINE VANCOMYCIN DOSING PARAMETERS [J].
BIRT, JK ;
CHANDLER, MHH .
THERAPEUTIC DRUG MONITORING, 1990, 12 (02) :206-209
[2]  
CANTU TG, 1994, CLIN INFECT DIS, V18, P533
[3]  
COMINO MA, 1987, AM J MED, V83, P1091
[4]   VANCOMYCIN TREATMENT OF BACTEREMIA CAUSED BY OXACILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS - COMPARISON WITH BETA-LACTAM ANTIBIOTIC-TREATMENT OF BACTEREMIA CAUSED BY OXACILLIN-SENSITIVE STAPHYLOCOCCUS-AUREUS [J].
CRAVEN, DE ;
KOLLISCH, NR ;
HSIEH, CR ;
CONNOLLY, MG ;
MCCABE, WR .
JOURNAL OF INFECTIOUS DISEASES, 1983, 147 (01) :137-143
[5]   Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies [J].
deGatta, MDF ;
Calvo, MV ;
Hernandez, JM ;
Caballero, D ;
SanMiguel, JF ;
DominguezGil, A .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (03) :332-340
[6]   Antibiotic treatment of febrile episodes in neutropenic cancer patients - Clinical and economic considerations [J].
deLalla, F .
DRUGS, 1997, 53 (05) :789-804
[7]   MILD NEPHROTOXICITY ASSOCIATED WITH VANCOMYCIN USE [J].
DOWNS, NJ ;
NEIHART, RE ;
DOLEZAL, JM ;
HODGES, GR .
ARCHIVES OF INTERNAL MEDICINE, 1989, 149 (08) :1777-1781
[8]  
DUFFULL SB, 1994, ADVERSE DRUG REACT T, V13, P103
[9]  
EDWARDS DJ, 1987, CLIN PHARMACY, V6, P652
[10]  
Elting LS, 1998, CANCER, V83, P2597, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2597::AID-CNCR27>3.0.CO